Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Prostate Disease: Pathogenesis, Diagnosis, and Therapy
share announcement

Prostate Disease: Pathogenesis, Diagnosis, and Therapy

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 4531

Special Issue Editors

Dr. Po-Fan Hsieh

E-Mail Website
Guest Editor
1. Department of Urology, China Medical University Hospital, Taichung 404, Taiwan
2. School of Medicine, China Medical University, Taichung 404, Taiwan
Interests: prostate cancer; minimal invasive surgery; focal therapy; targeted biopsy; urolithiasis
Dr. Chi-Ping Huang

E-Mail Website
Guest Editor
1. Department of Urology, China Medical University Hospital, Taichung 404, Taiwan
2. School of Medicine, China Medical University, Taichung 404, Taiwan
Interests: prostate cancer; urothelial cancer; kidney cancer; minimal invasive surgery

Special Issue Information

Dear Colleagues,

The prostate is an important accessory organ of the male genitourinary tract. The endocrine and exocrine function of the prostate play important roles in reproductive function. The prostatic urethra and sphincter also help control urinary function.

The incidence of prostate diseases, including benign prostate hyperplasia and prostate cancer, increase with age. Prostate cancer is the most common noncutaneous malignancy in males. Many elder males are also bothered by prostate hyperplasia. Factors such as lifestyle, dietary habit, ethnicity, family history, obesity, and smoking are also responsible for the formation and progression of prostate diseases.

In the last decade, there were great advancements in the management of prostate disease. For example, the diagnosis of prostate cancer evolved from systematic biopsy to MRI-targeted biopsy. Much more attention has been gained in the treatment of early prostate cancer using focal therapy. Novel hormone agents, radium-223, PARP inhibitors, and PSMA-based radionuclide therapy have revolutionized the treatment for metastatic prostate cancer. Technological advances including laser surgery, water vaporization, and arterial embolization also offer safer treatment alternatives for patients with prostate hyperplasia.

The Special Issue entitled “Prostate Disease: Pathogenesis, Diagnosis, and Therapy” aims to publish original research articles and review in the field of prostate diseases. The new advances in pathogenesis, diagnosis, and therapy for prostate cancer or benign prostate hyperplasia are highlighted.

Dr. Po-Fan Hsieh
Dr. Chi-Ping Huang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • benign prostate hyperplasia
  • pathogenesis
  • diagnosis
  • therapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

10 pages, 228 KiB  
Article
Post-Voided Residual Ratio Does Not Predict Trifecta Outcome after Transurethral Resection of Prostate
by Riccardo Lombardo, Nicola Ghezzo, Luca Sarcinelli, Beatrice Turchi, Filippo Zammitti, Antonio Franco, Antonio Nacchia, Antonio Cicione, Giorgia Tema, Antonio Luigi Pastore, Giorgio Guarnotta, Andrea Fuschi, Yazan Al Salhi, Andrea Tubaro and Cosimo De Nunzio
Life 2024, 14(4), 445; https://doi.org/10.3390/life14040445 - 27 Mar 2024
Viewed by 557
Abstract
The purpose of this study was to assess the importance of the post-void residual (PVR) ratio (PVR ratio) in achieving a favorable trifecta outcome for patients suffering from lower urinary tract symptoms and benign prostatic enlargement (LUTS-BPE) who undergo transurethral resection of the [...] Read more.
The purpose of this study was to assess the importance of the post-void residual (PVR) ratio (PVR ratio) in achieving a favorable trifecta outcome for patients suffering from lower urinary tract symptoms and benign prostatic enlargement (LUTS-BPE) who undergo transurethral resection of the prostate (TURP). Starting from 2015, a series of patients with LUTS-BPE who underwent TURP were included in a forward-looking study. These patients were assessed using the international prostate symptom score (IPSS) screening tool, uroflowmetry, and a transrectal ultrasound to measure prostate volume (TRUS). Both the PVR urine volume and the PVR ratio (PVR-R), which is the PVR as a percentage of total bladder volume (voided volume + PVR), were measured. The assessment of outcomes was based on the trifecta favorable outcome, defined as meeting all of the following criteria: (1) absence of perioperative complications, (2) a postoperative IPSS of less than eight, and (3) a postoperative maximum urinary flow rate (Qmax) greater than 15 mL/s. A total of 143 patients were included, with a median age of 70 years (interquartile range 65–73). Of these, 58% (83/143) achieved a positive trifecta outcome. Upon conducting a multivariate analysis, both IPSS and Qmax were identified as predictors of a positive trifecta outcome, whereas the PVR-R did not prove to be an independent predictor. In summary, it was found that preoperative IPSS and Qmax are indicative of a trifecta outcome following TURP, whereas PVR-R is not. Full article
(This article belongs to the Special Issue Prostate Disease: Pathogenesis, Diagnosis, and Therapy)

Review

Jump to: Research, Other

19 pages, 802 KiB  
Review
Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques
by Thomas Hughes, Philip Harper and Bhaskar K. Somani
Life 2023, 13(10), 2077; https://doi.org/10.3390/life13102077 - 18 Oct 2023
Viewed by 2467
Abstract
The management of benign prostatic obstruction (BPO) should involve a treatment algorithm that takes into account prostate size, and patient’s symptoms and preference with the aim of helping with urinary symptoms and enhance quality of life. The diagnostic assessment for men with lower [...] Read more.
The management of benign prostatic obstruction (BPO) should involve a treatment algorithm that takes into account prostate size, and patient’s symptoms and preference with the aim of helping with urinary symptoms and enhance quality of life. The diagnostic assessment for men with lower urinary tract symptoms (LUTS) should be comprehensive to help choose the best management strategy. Strategies from lifestyle modifications to medical treatment with alpha blockers and/or 5-alpha-reductase inhibitors to surgical procedures can all be used in the management algorithm. Surgical management ranges from transurethral resection of prostate (TURP) to minimally invasive surgical therapies (MIST) including laser therapies such as Holmium laser enucleation (HoLEP) and photoselective vaporisation (PVP), aquablation, Rezūm system, prostate artery embolisation (PAE), prostatic urethral lift (PUL), temporary implantable nitinol device (iTind) and Optilume BPH catheter system. BPO is a common urological condition that has a significant impact on quality of life and economic burden globally and is likely to become increasingly prevalent with an ageing population. Selecting the most appropriate treatment modality will depend on the individual patient preferences, availability of resources, cost, anatomical factors and the goals of treatment. Full article
(This article belongs to the Special Issue Prostate Disease: Pathogenesis, Diagnosis, and Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

13 pages, 441 KiB  
Systematic Review
A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?
by Jianliang Liu, Jordan Santucci, Dixon T. S. Woon, Rick Catterwell, Marlon Perera, Declan G. Murphy and Nathan Lawrentschuk
Life 2024, 14(1), 76; https://doi.org/10.3390/life14010076 - 2 Jan 2024
Cited by 2 | Viewed by 1191
Abstract
Active surveillance remains a treatment option for low- to intermediate-risk prostate cancer (PCa) patients. Prostate-specific membrane antigen positron emission tomography and computed tomography (PSMA PET/CT) has emerged as a useful modality to assess intraprostatic lesions. This systematic review aims to evaluate PSMA PET/CT [...] Read more.
Active surveillance remains a treatment option for low- to intermediate-risk prostate cancer (PCa) patients. Prostate-specific membrane antigen positron emission tomography and computed tomography (PSMA PET/CT) has emerged as a useful modality to assess intraprostatic lesions. This systematic review aims to evaluate PSMA PET/CT in localized low- to intermediate-risk PCa to determine its role in active surveillance. Following PRISMA guidelines, a search was performed on Medline, Embase, and Scopus. Only studies evaluating PSMA PET/CT in localized low- to intermediate-risk PCa were included. Studies were excluded if patients received previous treatment, or if they included high-risk PCa. The search yielded 335 articles, of which only four publications were suitable for inclusion. One prospective study demonstrated that PSMA PET/CT-targeted biopsy has superior diagnostic accuracy when compared to mpMRI. One prospective and one retrospective study demonstrated MRI occult lesions in 12.3–29% of patients, of which up to 10% may harbor underlying unfavorable pathology. The last retrospective study demonstrated the ability of PSMA PET/CT to predict the volume of Gleason pattern 4 disease. Early evidence demonstrated the utility of PSMA PET/CT as a tool in making AS safer by detecting MRI occult lesions and patients at risk of upgrading of disease. Full article
(This article belongs to the Special Issue Prostate Disease: Pathogenesis, Diagnosis, and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop